drugset / Trial / NCT05316493

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

NCT05316493

Phase 2/3 Recruiting 172 enrolled Xiaojun Chen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

Timeline

Start
2022-06-13
Primary completion
2026-02-28
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 52 mg Other
Subject Megestrol Acetate Other / unclassified 160 mg Oral